Premium
Polymorphonuclear neutrophils and cancer: Intense and sustained neutrophilia as a treatment against solid tumors
Author(s) -
Souto Juan Carlos,
Vila Luis,
Brú Antonio
Publication year - 2011
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.20185
Subject(s) - neutrophilia , immune system , inflammation , cancer , medicine , immunology , cancer research , granulocyte , cancer cell , tumor microenvironment , clinical trial , solid tumor , granulocyte colony stimulating factor , effector , chemotherapy
Polymorphonuclear neutrophils (PMN) are the most abundant circulating immune cells and represent the first line of immune defense against infection. This review of the biomedical literature of the last 40 years shows that they also have a powerful antitumoral effect under certain circumstances. Typically, the microenvironment surrounding a solid tumor possesses many of the characteristics of chronic inflammation, a condition considered very favorable for tumor growth and spread. However, there are many circumstances that shift the chronic inflammatory state toward an acute inflammatory response around a tumor. This shift seems to convert PMN into very efficient anticancer effector cells. Clinical reports of unexpected antitumoral effects linked to the prolonged use of granulocyte colony‐stimulating factor, which stimulates an intense and sustained neutrophilia, suggest that an easy way to fight solid tumors would be to encourage the development of intense peritumoral PMN infiltrates. Specifically designed clinical trials are urgently needed to evaluate the safety and efficacy of such drug‐induced neutrophilia in patients with solid tumors. This antitumoral role of neutrophils may provide new avenues for the clinical treatment of cancer. © 2009 Wiley Periodicals, Inc. Med Res Rev, 31, No. 3, 311–363, 2011